XTL Biopharmaceuticals Ltd (XTLB) - Net Assets
Based on the latest financial reports, XTL Biopharmaceuticals Ltd (XTLB) has net assets worth ILA5.43 Million ILA (≈ $14.57K USD) as of December 2024. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (ILA8.55 Million ≈ $22.92K USD) and total liabilities (ILA3.12 Million ≈ $8.35K USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check asset resilience ratio of XTL Biopharmaceuticals Ltd to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ILA5.43 Million |
| % of Total Assets | 63.57% |
| Annual Growth Rate | -2.0% |
| 5-Year Change | -13.03% |
| 10-Year Change | 11.21% |
| Growth Volatility | 63.1 |
XTL Biopharmaceuticals Ltd - Net Assets Trend (2013–2024)
This chart illustrates how XTL Biopharmaceuticals Ltd's net assets have evolved over time, based on quarterly financial data. Also explore how large is XTL Biopharmaceuticals Ltd's balance sheet for the complete picture of this company's asset base.
Annual Net Assets for XTL Biopharmaceuticals Ltd (2013–2024)
The table below shows the annual net assets of XTL Biopharmaceuticals Ltd from 2013 to 2024. For live valuation and market cap data, see XTL Biopharmaceuticals Ltd market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | ILA5.43 Million ≈ $14.57K |
+144.82% |
| 2023-12-31 | ILA2.22 Million ≈ $5.95K |
-44.49% |
| 2022-12-31 | ILA4.00 Million ≈ $10.72K |
-25.01% |
| 2021-12-31 | ILA5.33 Million ≈ $14.30K |
-14.66% |
| 2020-12-31 | ILA6.25 Million ≈ $16.75K |
-10.47% |
| 2019-12-31 | ILA6.98 Million ≈ $18.71K |
-16.13% |
| 2018-12-31 | ILA8.32 Million ≈ $22.31K |
+129.95% |
| 2017-12-31 | ILA3.62 Million ≈ $9.70K |
+34.69% |
| 2016-12-31 | ILA2.69 Million ≈ $7.20K |
-45.02% |
| 2015-12-31 | ILA4.89 Million ≈ $13.10K |
+4.45% |
| 2014-12-31 | ILA4.68 Million ≈ $12.54K |
-31.04% |
| 2013-12-31 | ILA6.79 Million ≈ $18.19K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to XTL Biopharmaceuticals Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1293600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | ILA164.44 Million | 3025.65% |
| Total Equity | ILA5.43 Million | 100.00% |
XTL Biopharmaceuticals Ltd Competitors by Market Cap
The table below lists competitors of XTL Biopharmaceuticals Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bank Mayapada Internasional
JK:MAYA
|
$4.25 Million |
|
Corus Entertainment Inc
TO:CJR-B
|
$4.26 Million |
|
Alliance Pharma plc
LSE:APH
|
$4.26 Million |
|
Horus AG
STU:HRU
|
$4.26 Million |
|
Yunnan Water Investment Co. Limited
F:2WI
|
$4.25 Million |
|
Altur Slatina
RO:ALT
|
$4.25 Million |
|
FEEDBACK PLC LS-5
F:GZM0
|
$4.25 Million |
|
RWS Holdings PLC
LSE:RWS
|
$4.25 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in XTL Biopharmaceuticals Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,220,000 to 5,435,000, a change of 3,215,000 (144.8%).
- Net loss of 1,027,000 reduced equity.
- New share issuances of 1,460,000 increased equity.
- Other factors increased equity by 2,782,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ILA-1.03 Million | -18.9% |
| Share Issuances | ILA1.46 Million | +26.86% |
| Other Changes | ILA2.78 Million | +51.19% |
| Total Change | ILA- | 144.82% |
Book Value vs Market Value Analysis
This analysis compares XTL Biopharmaceuticals Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 291.90x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 132.60x to 291.90x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | ILA0.01 | ILA1.80 | x |
| 2020-12-31 | ILA0.01 | ILA1.80 | x |
| 2021-12-31 | ILA0.01 | ILA1.80 | x |
| 2022-12-31 | ILA0.01 | ILA1.80 | x |
| 2023-12-31 | ILA0.00 | ILA1.80 | x |
| 2024-12-31 | ILA0.01 | ILA1.80 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently XTL Biopharmaceuticals Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.90%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -227.72%
- • Asset Turnover: 0.05x
- • Equity Multiplier: 1.57x
- Recent ROE (-18.90%) is above the historical average (-34.91%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -39.52% | 0.00% | 0.00x | 1.28x | ILA-3.10 Million |
| 2014 | -54.23% | 0.00% | 0.00x | 1.21x | ILA-2.99 Million |
| 2015 | -88.25% | 0.00% | 0.00x | 1.09x | ILA-4.80 Million |
| 2016 | -94.72% | 0.00% | 0.00x | 1.12x | ILA-2.81 Million |
| 2017 | -21.58% | 0.00% | 0.00x | 1.82x | ILA-1.14 Million |
| 2018 | 35.88% | 0.00% | 0.00x | 1.03x | ILA2.15 Million |
| 2019 | -19.30% | 0.00% | 0.00x | 1.03x | ILA-2.04 Million |
| 2020 | -12.51% | 0.00% | 0.00x | 1.04x | ILA-1.41 Million |
| 2021 | 8.16% | 0.00% | 0.00x | 1.24x | ILA-98.30K |
| 2022 | -33.71% | 0.00% | 0.00x | 1.05x | ILA-1.75 Million |
| 2023 | -80.27% | 0.00% | 0.00x | 1.09x | ILA-2.00 Million |
| 2024 | -18.90% | -227.72% | 0.05x | 1.57x | ILA-1.57 Million |
Industry Comparison
This section compares XTL Biopharmaceuticals Ltd's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $104,302,885
- Average return on equity (ROE) among peers: -112.41%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| XTL Biopharmaceuticals Ltd (XTLB) | ILA5.43 Million | -39.52% | 0.57x | $4.25 Million |
| BioLine RX Ltd (BLRX) | $31.77 Million | -32.03% | 0.14x | $9.10 Million |
| BioLight Life Sciences Ltd (BOLT) | $13.31 Million | 0.00% | 0.69x | $7.66 Million |
| Bonus Biogroup (BONS) | $84.43 Million | -106.69% | 0.24x | $123.99 Million |
| Can Fite Biopharma Ltd (CANF) | $2.44 Million | -516.99% | 2.35x | $5.56 Million |
| Clal Biotechnology Industries Ltd (CBI) | $808.20 Million | -3.45% | 0.28x | $12.61 Million |
| Compugen (CGEN) | $19.58 Million | -61.30% | 0.49x | $201.26 Million |
| DNA Biomed Solns (DNA) | $10.45 Million | 0.00% | 0.61x | $34.04 Million |
| Enlivex Therapeutics Ltd (ENLV) | $8.70 Million | -184.18% | 0.22x | $458.60K |
| Evogene (EVGN) | $56.88 Million | -46.07% | 0.26x | $4.88 Million |
| Kadimastem Ltd (KDST) | $7.28 Million | -173.39% | 0.71x | $22.18 Million |
About XTL Biopharmaceuticals Ltd
XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company L… Read more